This milestone marks transition of Perfuse Therapeutics to a clinical-stage company SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering ...

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma. PR Newswire. SAN FRANCISCO, May 6, 2025 ...

Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive 24-week ...

About PER-001 Intravitreal Implant, a Long-Acting Endothelin Receptor Antagonist PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin ...

Perfuse Therapeutics is a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery ...

Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma. The trial will enroll ...

Perfuse Therapeutics' drug-device PER-001 shows promise in treating glaucoma and diabetic retinopathy, potentially restoring vision in patients. San Francisco Business Times.

据官方消息，由区块链基础设施自动化公司 Zeeve 提供支持的平行链部署工具 Perfuse 已获得 Web3 基金会 Decentralized Futures 资助，具体金额暂未披露，该 ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

Tuesday, 02 January 2024 12:17 GMT 02 January 2024 12:17 GMT. عربي ...